GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (OTCPK:BMKDF) » Definitions » Equity-to-Asset

Biomark Diagnostics (Biomark Diagnostics) Equity-to-Asset

: -0.42 (As of Dec. 2023)
View and export this data going back to 2015. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Biomark Diagnostics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-0.42 Mil. Biomark Diagnostics's Total Assets for the quarter that ended in Dec. 2023 was $1.01 Mil. Therefore, Biomark Diagnostics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -0.42.

The historical rank and industry rank for Biomark Diagnostics's Equity-to-Asset or its related term are showing as below:

BMKDF' s Equity-to-Asset Range Over the Past 10 Years
Min: -59.79   Med: -1.58   Max: 0.64
Current: -0.42

During the past 10 years, the highest Equity to Asset Ratio of Biomark Diagnostics was 0.64. The lowest was -59.79. And the median was -1.58.

BMKDF's Equity-to-Asset is ranked worse than
92.47% of 239 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59 vs BMKDF: -0.42

Biomark Diagnostics Equity-to-Asset Historical Data

The historical data trend for Biomark Diagnostics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomark Diagnostics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -35.08 -0.69 -0.08 -0.43 -1.57

Biomark Diagnostics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.98 -1.57 -1.58 -1.82 -0.42

Competitive Comparison

For the Diagnostics & Research subindustry, Biomark Diagnostics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomark Diagnostics Equity-to-Asset Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Biomark Diagnostics's Equity-to-Asset falls into.



Biomark Diagnostics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Biomark Diagnostics's Equity to Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Equity to Asset (A: Mar. 2023 )=Total Stockholders Equity/Total Assets
=-0.84/0.535
=-1.57

Biomark Diagnostics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-0.417/1.006
=-0.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomark Diagnostics  (OTCPK:BMKDF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Biomark Diagnostics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Biomark Diagnostics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomark Diagnostics (Biomark Diagnostics) Business Description

Traded in Other Exchanges
Address
130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early treatment for cancer. Its research and development are focused on the role that metabolomics plays in early cancer detection. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.

Biomark Diagnostics (Biomark Diagnostics) Headlines

No Headlines